JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY
·
2014
·Vol. 302
·期 1
·123-130
·
IF 1.415
Sun Zhi-Zhong,Wei Hong-Yuan,Wang Guan-Quan,Zhou Zhi-Jun,He Jia-Heng,Wang Jing,Luo Shun-Zhong
[ 131 I]-5,10,15,20-tetrakis(4-hydroxyphenyl)porphyrin and [ 131 I]-5-(4-aminophenyl)-10,15,20-triphenylporphyrin ( 131 I-TPPOH and 131 I-TPPNH 2 ) were prepared and their biodistribution properties were evaluated in normal Kunming (KM) mice and SMMC-7721 tumor-bearing BALB/c mice. The optimized labeling yields were 98 and 96 % for 131 I-TPPOH and 131 I-TPPNH 2 , respectively. They were stable in vitro saline and in vivo. Both compounds had a specific affinity to liver and lung, and mainly metabolized through liver. They showed a time-dependent accumulation and retainable characteristics in SMMC-7721 tumor. These results supported their potential value for targeted tumor therapy agents.
研究领域:
放射医学
·
肿瘤学
·
药理学
✓ 已验证
DOI
高影响因子
Frontiers in Oncology
·
2022
·
IF 5.738
Zhang Xuemei,Yan Ziyu,Meng Zhaowei,Li Ning,Jia Qiang,Shen Yiming,Ji Yanhui
Objectives: Anaplastic thyroid cancer (ATC) cells cannot retain the radionuclide iodine 131 (131I) for treatment due to the inability to uptake iodine. This study investigated the feasibility of combining radionuclides with photothermal agents in the diagnosis and treatment of ATC.Methods: 131I was labeled on human serum albumin (HSA) by the standard chloramine T method. 131I-HSA and indocyanine green (ICG) were non-covalently bound by a simple stirring to obtain 131I-HSA-ICG nanoparticles. Characterizations were performed in vitro. The cytotoxicity and imaging ability were investigated by cell/in vivo experiments. The radio-photothermal therapy efficacy of the nanoparticles was evaluated at the cellular and in vivo levels.Results: The synthesized nanoparticles had a suitable size (25–45 nm) and objective biosafety. Under the irradiation of near-IR light, the photothermal conversion efficiency of the nanoparticles could reach 24.25%. In vivo fluorescence imaging and single-photon emission CT (SPECT)/CT imaging in small animals confirmed that I-HSA-ICG/131I-HSA-ICG nanoparticles could stay in tumor tissues for 4–6 days. Compared with other control groups, 131I-HSA-ICG nanoparticles had the most significant ablation effect on tumor cells under the irradiation of an 808-nm laser.Conclusions: In summary, 131I-HSA-ICG nanoparticles could successfully perform dual-modality imaging and treatment of ATC, which provides a new direction for the future treatment of iodine-refractory thyroid cancer.
研究领域:
肿瘤学
·
核医学
·
生物材料学
✓ 已验证
产品关联
DOI
PubMed
高影响因子
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY
·
2016
·Vol. 311
·期 3
·1697-1708
·
IF 0.983
Xie Qinghua,Li Xia,Wang Guanquan,Hou Xuan,Wang Yujun,Yu Hongbo,Qu Changfa,Luo Shunzhong,Cui Yali,Xia Chuanqin,Wang Ruibing
Here we reported the radiolabeling and evaluation of a novel 131 I-radiolabeled quercetin for the treatment of dedifferentiated thyroid cancers. The human thyroid cancer cell lines (FTC-133, TT and DRO) experienced much higher uptake of 131 I-quercetin as compared to the free 131 I. And the proliferation inhibition rate of 131 I-quercetin on in vitro DRO cell line was 86.87 ± 7.15%. Biodistribution and SPECT analysis demonstrated that the injected radioactivity mainly accumulated in tumors. The tumor volume in the treatment group was dramatically inhibited in comparison with the control group.
研究领域:
核医学
·
肿瘤学
·
药理学
✓ 已验证
产品关联
DOI
高影响因子
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
·
2024
·
IF 8.6
Lu Ganghua,Gao Dingwei,Jiang Wen,Yu Xiaqing,Tong Junyu,Liu Xiaoyan,Qiao Tingting,Wang Ru,Zhang Mengyu,Wang Shaoping,Yang Jianshe,Li Dan,Lv Zhongwei
Background Despite the potential radiotoxicity in differentiated thyroid cancer (DTC) patients with high-dose 131 I therapy, the alterations and regulatory mechanisms dependent on intestinal microecology remain poorly understood. We aimed to identify the characteristics of the gut microbiota and metabolites in DTC patients suffering from high-dose 131 I therapy and explore the radioprotective mechanisms underlying arachidonic acid (ARA) treatment. Methods A total of 102 patients with DTC were recruited, with fecal samples collected before and after 131 I therapy for microbiome and untargeted and targeted metabolomic analyses. Mice were exposed to total body irradiation with ARA replenishment and antibiotic pretreatment and were subjected to metagenomic, metabolomic, and proteomic analyses. Results 131 I therapy significantly changed the structure of gut microbiota and metabolite composition in patients with DTC. Lachnospiraceae were the most dominant bacteria after 131 I treatment, and metabolites with decreased levels and pathways related to ARA and linoleic acid were observed. In an irradiation mouse model, ARA supplementation not only improved quality of life and recovered hematopoietic and gastrointestinal systems but also ameliorated oxidative stress and inflammation and preserved enteric microecology composition. Additionally, antibiotic intervention eliminated the radioprotective effects of ARA. Proteomic analysis and ursolic acid pretreatment showed that ARA therapy greatly influenced intestinal lipid metabolism in mice subjected to irradiation by upregulating the expression of hydroxy-3-methylglutaryl-coenzyme A synthase 1. Conclusion These findings highlight that ARA, as a key metabolite, substantially contributes to radioprotection. Our study provides novel insights into the pivotal role that the microbiota-metabolite axis plays in radionuclide protection and offers effective biological targets for treating radiation-induced adverse effects.
研究领域:
肿瘤学
·
胃肠病学
·
放射生物学
·
微生物学
·
代谢组学
✓ 已验证
产品关联
DOI
PubMed
高影响因子
Advanced Healthcare Materials
·
2020
·Vol. 10
·期 3
·2001029
·
IF 7.367
Shuo Huang,Linlin Zhang,Miaomiao Xu,Chao Li,Hongliang Fu,Jie Huang,Xin Jin,Sheng Liang,Hui Wang
New radionuclide-labeled targeting nanocarrier systems have generated new opportunities for tumor treatment and imaging. Nevertheless, such therapeutic strategy is clinically unfeasible on anaplastic thyroid carcinoma (ATC) patients, because of lacking suitable targets and resistance to radiation. In order to figure out a potential treatment, immuno-histochemical staining is performed in human ATC tissue species and high expression of cluster determinant 44 (CD44) is found. Therefore, a CD44-targeted delivery system is designed and constructed by self-assembly of tyrosine (Tyr)–hyaluronic acid (HA)–polyethyleneimine (PEI), which can radiolabel 131/125 I and load a p53 mutant restoring regent, Prima-1. The 125 I-labeled nanocomposites display an impressive tumor imaging as well as a long radiation treatment cycle. The 131 I-labeled nanoparticles show remarkable anti ATC-tumor effects in vitro and in vivo, due to radiosensitization of Prima-1 by reactivation of the p53 mutants.
研究领域:
纳米技术
·
肿瘤学
·
放射学
·
分子生物学
✓ 已验证
产品关联
DOI
PubMed
高影响因子
BIOMATERIALS
·
2024
·
IF 12.8
Jingjing Shen,Kai Feng,Jing Yu,Yaxuan Zhao,Ruifang Chen,Hehua Xiong,Yiling Ruan,Zhengtao Xu,Tao Zhang,Xiaolian Sun
Ferroptosis is an iron-dependent form of programmed cell death with the potential to reverse traditional cancer therapy resistance. The combination of ferroptosis with chemotherapy, photodynamic therapy and X-ray therapy has demonstrated remarkably improved therapeutic efficiency. Radiopharmaceutical therapy (RPT) is an emerging approach that achieves precise radiation to diseased tissues via radionuclide delivery. However, insufficient accumulation and retention of therapeutic radiopharmaceuticals in tumor region as well as cancer radioresistance impact treatment efficacy. Here, a nanoassembly of renal clearable ultrasmall iron nanoparticles (USINPs) and 131 I-aPD-L1 is prepared via the affinity of fluorophenylboronic acid modified on the USINPs with 131 I-aPD-L1. The 150 nm USINAs( 131 I-aPD-L1) nanoassembly is stable in blood circulation, effectively targets to the tumor and disassembles in the presence of ATP in the tumor microenvironment. Both in vitro and in vivo experiments prove that USINPs-induced ferroptosis boosted the tumor radiosensitization to 131 I while 131 I-mediated RPT further enhanced ferroptosis. Meanwhile, the immunogenic cell death caused by RPT and ferroptosis combined with PD-L1 immune checkpoint blockade therapy exhibits a strong antitumor immunity. This study provides a novel way to improve the tumor accumulation of ferroptosis inducer and radiopharmaceuticals, insights into the interaction between RPT and ferroptosis and an effective SPECT-guided ferroptosis-enhanced radio-immunotherapy.
研究领域:
纳米技术
·
放射学
·
肿瘤学
·
免疫治疗
·
药剂学
✓ 已验证
产品关联
DOI
PubMed
高影响因子
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY
·
2018
·Vol. 316
·期 2
·685-690
·
IF 1.181
Song Hu,Wang Yunhan,Wang Jing,Wang Guanquan,He Jiaheng,Wei Hongyuan,Luo Shunzhong
For the superiority of graphene quantum dots (GQDs) in bioimaging and drug delivery carrier, GQDs bring new opportunities for theranostics of diseases. In this study, GQDs were successfully prepared and labeled with 131 I. The in vitro properties, biodistribution and SPECT imaging of 131 I-GQDs were investigated. The uptake of 131 I-GQDs at tumor sites can be clearly observed via SPECT imaging and T/B and T/M ratios increase with increasing time, which can contribute to enhanced permeability and retention (EPR) effect.
研究领域:
核医学
·
放射学
·
材料科学
·
生物医学工程
✓ 已验证
产品关联
DOI
高影响因子
MOLECULAR PHARMACEUTICS
·
2021
·
IF 4.939
Huan Ma,Feize Li,Guohua Shen,Huawei Cai,Weihao Liu,Tu Lan,Yuanyou Yang,Jijun Yang,Jiali Liao,Ning Liu
As an excellent target for cancer theranostics, fibroblast activation protein (FAP) has become an attractive focus in cancer research. A class of FAP inhibitors (FAPIs) with a N-(4-quinolinoyl)-Gly-(2-cyanopyrrolidine) scaffold were developed, which displayed nanomolar affinity and high selectivity. Compared with 90Y, 177Lu, 225Ac, and 188Re, 211At seems to be more favored as a therapeutic candidate for FAPI tracers which have fast washout and short retention in tumor sites. Thus, the current study reported the synthesis of two FAPI precursors for 211At and 131I labeling and the preliminary evaluation of 131I-labeled FAPI analogues for cancer theranostics. FAPI variants with stannyl precursors were successfully synthesized and labeled with 131I using a radioiododestannylation reaction. Two radioactive tracers were obtained with high radiochemical purity over 99% and good radiochemical yields of 58.2 ± 1.78 and 59.5 ± 4.44% for 131I-FAPI-02 and 131I-FAPI-04, respectively. Both tracers showed high specific binding to U87MG cells in comparison with little binding to MCF-7 cells. Compared to 131I-FAPI-02, 131I-FAPI-04 exhibited higher affinity, more intracellular uptake, and longer retention time in vitro. Biodistribution studies revealed that both tracers were mainly excreted through the kidneys as well as the hepatobiliary pathway due to their high lipophilicity. In addition, higher accumulation, longer dwell time, and increased tumor-to-organ ratios were achieved by 131I-FAPI-04, which was clearly demonstrated by SPECT/CT imaging. Furthermore, intratumor injection of 131I-FAPI-04 significantly suppressed the tumor growth in U87MG xenograft mice without significant toxicity observed. The above results implied that FAP-targeted alpha endoradiotherapy (specific to 211At) should be used to treat tumors in the near future, considering the chemical similarity between iodine and astatine can ensure the labeling of the latter onto the designed FAPIs.
研究领域:
肿瘤学
·
核医学
·
分子影像学
✓ 已验证
DOI
PubMed
高影响因子
ACS Applied Bio Materials
·
2026
·
IF 5.6
Ruitong Hou,Yuying Yu,Xuanyang Li,Tianzhen Ye,Zihao Tang,Fuyuan Tan,Yuanyou Yang,Jiali Liao,Ning Liu,Feize Li
It is imperative to optimize the therapeutic efficacy of anticancer medicine for translation from preclinical investigation to clinical practice. Typically, a single antitumor protocol usually cannot suppress tumor growth efficiently while sparing the side effects on normal organs or tissues. Here, we proposed a strategy combining radiopharmaceutical with photothermal therapy, which involved the construction of 131I-radiolabeled carbon quantum dots (131I-CQDs) with high photoactivity. The designed CQDs were well prepared and characterized, of which the photothermal capacity was demonstrated through a comprehensive evaluation in vitro and in vivo. More interestingly, 131I, a pivotal therapeutic radionuclide in biomedicine, can be conjugated with CQDs with high radiochemical yield, and the prepared 131I-CQDs can keep approximately 75% radiochemical encapsulation in different physiological media after a week. 131I-CQDs exhibit high cancer cell binding affinity, good endocytosis, and low efflux on 4T1 cells, demonstrating enhanced therapeutic effects in cell viability assays. In animal models, 131I-CQDs have manifested synergistic anticancer potential from radionuclide and photothermal therapy, capable of impeding cancer growth and prolonging survival of murine tumor-bearing models. The outcomes of this study suggest that CQD-derived platforms can combine photothermal and 131I radionuclide oncotherapy, providing an alternative avenue to promoting the application of nanoscale materials in anticancer fields.
✓ 已验证
DOI
PubMed
高影响因子
Advanced Healthcare Materials
·
2020
·Vol. 10
·期 5
·2000802
·
IF 7.367
Qiang Wang,Nian Liu,Zhenyu Hou,Junpeng Shi,Xinhui Su,Xiaolian Sun
Radionuclide with Cerenkov radiation (CR) can serve as an internal excitation source to activate photosensitizers for photodynamic therapy (PDT) in deep tumor. However, the low efficiency of CR limits its therapeutic efficacy. A 131 I labeled zinc tetra(4-carboxyphenoxy) phthalocyaninate (ZnPcC4) conjugated Cr 3+ -doped zinc gallate (ZnGa 2 O 4 :Cr 3+ , ZGCs) nanoplatform ( 131 I-ZGCs-ZnPcC4) is developed for radiotherapy (RT) and radiation-induced PDT. 131 I can not only activate ZGCs for long-lasting luminescence via both Cerenkov luminescence (CL) and ionizing radiation, which further continuously activate photosensitizer ZnPcC4 for PDT, but also can directly kill cancerous cells. This 131 I-ZGCs-ZnPcC4 exhibits excellent tumor inhibition both in vitro and in vivo. Combining self-activated PDT and RT, it is believed that the 131 I-ZGCs-ZnPcC4 can greatly benefit the deep tumor therapy.
研究领域:
医学
·
生物材料学
·
放射生物学
✓ 已验证
DOI
高影响因子
Journal of Materials Chemistry B
·
2022
·Vol. 10
·期 13
·2251-2259
·
IF 7.571
Qiqi Wang,Chunmei Lu,Ke Li,Yongmei Xia,Ling Qiu,Jianguo Lin
Targeted radionuclide therapy (TRT) has been a promising strategy for cancer therapy, which can inhibit or kill cancer cells by selectively delivering radionuclide to target tissues. Herein, a legumain-targeted therapeutic agent [131I]MAAN was synthesized that was capable of condensation and self-assembly in response to legumain and glutathione (GSH) in tumor cells to enhance the therapeutic effect. This radiopharmaceutical has been acquired with a radiochemical yield (RCY) of 57.8 ± 5.3% and a high radiochemical purity (RCP) of more than 95%. In vitro cellular uptake assay suggested that [131I]MAAN had a 2-fold higher uptake in legumain-positive HCT116 cells than in the legumain-negative SKOV3 cells, revealing the specificity of the agent for legumain. Similarly, the in vitro cytotoxicity assay showed that [131I]MAAN possessed a more obvious killing effect on HCT116 cells. Cerenkov imaging with [131I]MAAN was carried out to generate clear tumor images. TRT with [131I]MAAN significantly inhibited the tumor growth and no obvious toxicity towards other normal organs was observed, indicating that it is a safe and effective treatment for cancers. Therefore, the agent [131I]MAAN holds great potential for the diagnosis and treatment of cancers with a high expression level of legumain.
研究领域:
放射学
·
肿瘤学
·
分子生物学
·
药学
✓ 已验证
DOI
PubMed
高影响因子
Theranostics
·
2018
·
IF 8.537
Qiufang Liu,Yuyi Qian,Panli Li,Sihang Zhang,Jianjun Liu,Xiaoguang Sun,Michael Fulham,Dagan Feng,Gang Huang,Wei Lu,Shaoli Song
Purpose: Transcatheter hepatic artery embolization therapy is a minimally invasive alternative for treating inoperable liver cancer but recurrence is frequent. Multifunctional agents, however, offer an opportunity for tumor eradication. In this study, we were aim to synthesized poly (lactic-co-glycolic acid) (PLGA) microspheres encapsulating hollow CuS nanoparticles (HCuSNPs) and paclitaxel (PTX) that were then labeled with radioiodine-131 ( 131 I) to produce 131 I-HCuSNPs-MS-PTX. This compound combines the multi-theranostic properties of chemotherapy, radiotherapy and photothermal therapy. In addition, it can also be imaged with single photon emission computed tomography (SPECT) imaging and photoacoustic imaging. Methods: We investigated the value of therapeutic and imaging of 131 I-HCuSNPs-MS-PTX in rats bearing Walker-256 tumor transplanted in the liver. After the intra-arterial (IA) injection of 131 I-HCuSNPs-MS-PTX, 18 F-Fluorodeoxyglucose ( 18 F-FDG) micro-positron emission tomography/computed tomography (micro-PET/CT) imaging was used to monitor the therapeutic effect. PET/CT findings were verified by immunohistochemical analysis. SPECT/CT and photoacoustic imaging were performed to demonstrate the distribution of 131 I-HCuSNPs-MS-PTX in vivo . Results : We found that embolization therapy in combination with chemotherapy, radiotherapy and photothermal therapy offered by 131 I-HCuSNPs-MS-PTX completely ablated the transplanted hepatic tumors at a relatively low dose. In comparison, embolization monotherapy or combination with one or two other therapies had less effective anti-tumor efficacy. The combination of SPECT/CT and photoacoustic imaging effectively confirmed microsphere delivery to the targeted tumors in vivo and guided the near-infrared laser irradiation. Conclusion : Our study suggests that there is a clinical theranostic potential for imaging-guided arterial embolization with 131 I-HCuSNPs-MS-PTX for the treatment of liver tumors.
研究领域:
肿瘤学
·
放射学
·
药理学
·
医学影像
✓ 已验证
产品关联
DOI
PubMed
高影响因子
危险品化学品经营许可证（带存储）